The asymmetric phase-transfer catalytic alkylation of peptides has been achieved by the use of designed C 2-symmetric chiral quaternary ammonium bromide 1 as catalyst. Excellent stereoselectivities were uniformly observed in the alkylation with a variety of alkyl halides and the efficiency of the transmission of stereochemical information was not affected by the side-chain structure of the preexisting amino acid residues. This method also enables an asymmetric construction of noncoded ␣,␣-dialkyl-␣-amino acid residues at the peptide terminal. Since this chirality can be efficiently transferred to the adjacent amino acid moiety, our approach provides a general procedure not only for the highly stereoselective terminal functionalization of peptides but also for the sequential asymmetric construction of unnatural oligopeptides, which should play a vital role in the peptide-based drug discovery process. M odification of peptides is an essential and flexible synthetic concept for efficient target screening and optimization of lead structures in the application of naturally occurring peptides as pharmaceuticals (1, 2). The direct introduction of side chains to a peptide backbone represents an attractive method for the preparation of various unnatural peptides. Achiral glycine subunit has generally been used for this purpose (3), and glycine enolates (4-14), glycine radicals (15-18), and glycine cation equivalents (19-22) have been exploited as reactive intermediates. However, the control of the stereochemical outcome of these processes in an absolute sense is a difficult task, especially in the modification of linear peptides, and hence development of an efficient and practical approach to establish sufficient stereoselectivity and general applicability has been eagerly awaited (12,23,24). Although the stereoselective phase-transfer alkylation of Schiff base-activated small peptides, which involves chirality transfer between two adjoining amino acid residues, appears to be an attractive method (6-8), it has never been developed to a useful level because of the lack of well designed, effective chiral catalysts. Here we describe our approach to this problem by using our recently developed, optically pure C 2 -symmetric quaternary ammonium salt 1 as catalyst (25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35). By fine-tuning the catalyst structure, a variety of new side chains can be introduced into the growing peptide terminal with remarkable stereoselectivity, and this newly created chirality can be efficiently transferred to an adjacent amino acid residue, thereby allowing the asymmetric construction of unnatural oligopeptides (36) (Scheme 1).
Experimental SectionGeneral. IR spectra were recorded on a Shimazu FT-IR 8200A spectrometer. 1 H NMR spectra were measured on a JEOL JNM-FX400 (400 MHz) spectrometer, and tetramethylsilane was used as internal standard (␦ ϭ 0). Splitting patterns are indicated as s, singlet; d, doublet; t, triplet; q, quartet; quint, quintet; sept, septet; m, multiplet; br, broad peak. Optical rotation...